Earnings Recaps

Browse reported earnings of the most popular stocks

Aug 14, 2026 Aug 13, 2026 Aug 12, 2026 Aug 11, 2026 Aug 10, 2026 Aug 9, 2026 Aug 8, 2026 Aug 7, 2026 Aug 6, 2026 Aug 5, 2026 Aug 4, 2026 Aug 3, 2026 Aug 2, 2026 Aug 1, 2026 Jul 31, 2026 Jul 30, 2026 Jul 29, 2026 Jul 28, 2026 Jul 27, 2026 Jul 26, 2026 Jul 25, 2026 Jul 24, 2026 Jul 23, 2026 Jul 22, 2026 Jul 21, 2026 Jul 20, 2026 Jul 19, 2026 Jul 18, 2026 Jul 17, 2026 Jul 16, 2026 Jul 12, 2026 Jul 11, 2026 Jul 10, 2026 Jul 9, 2026 Jul 3, 2026 Jul 2, 2026 Jul 1, 2026 Jun 30, 2026 Jun 28, 2026 Jun 27, 2026 Jun 26, 2026 Jun 25, 2026 Jun 24, 2026 Jun 20, 2026 Jun 19, 2026 Jun 18, 2026 Jun 17, 2026 Jun 15, 2026 Jun 14, 2026 Jun 13, 2026 Jun 12, 2026 Jun 11, 2026 Jun 10, 2026 Jun 9, 2026 Jun 6, 2026 Jun 5, 2026 Jun 4, 2026 Jun 3, 2026 Jun 2, 2026 Jun 1, 2026 May 31, 2026 May 30, 2026 May 29, 2026 May 28, 2026 May 27, 2026 May 26, 2026 May 24, 2026 May 23, 2026 May 22, 2026 May 21, 2026 May 20, 2026 May 19, 2026 May 18, 2026 May 17, 2026 May 16, 2026 May 15, 2026 May 14, 2026 May 13, 2026 May 12, 2026 May 11, 2026 May 10, 2026 May 9, 2026 May 8, 2026 May 7, 2026 May 6, 2026 May 5, 2026 May 4, 2026 May 3, 2026 May 2, 2026 May 1, 2026 Apr 30, 2026 Apr 29, 2026 Apr 23, 2026 Apr 22, 2026 Apr 21, 2026 Apr 20, 2026 Apr 18, 2026 Apr 17, 2026 Apr 16, 2026 Apr 15, 2026 Apr 14, 2026 Apr 13, 2026 Apr 10, 2026 Apr 9, 2026 Apr 8, 2026 Apr 7, 2026 Apr 2, 2026 Apr 1, 2026 Mar 31, 2026 Mar 30, 2026 Mar 26, 2026 Mar 25, 2026 Mar 20, 2026 Mar 19, 2026 Mar 18, 2026 Mar 17, 2026 Mar 16, 2026 Mar 13, 2026 Mar 12, 2026 Mar 11, 2026 Mar 9, 2026 Mar 7, 2026 Mar 6, 2026 Mar 5, 2026 Mar 4, 2026 Mar 3, 2026 Mar 2, 2026 Feb 28, 2026 Feb 27, 2026 Feb 26, 2026 Feb 25, 2026 Feb 24, 2026 Feb 23, 2026 Feb 21, 2026 Feb 20, 2026 Feb 19, 2026 Feb 18, 2026 Feb 17, 2026 Feb 14, 2026 Feb 13, 2026 Feb 12, 2026 Feb 11, 2026 Feb 10, 2026 Feb 9, 2026 Feb 7, 2026 Feb 6, 2026 Feb 5, 2026 Feb 4, 2026 Feb 3, 2026 Feb 2, 2026 Jan 31, 2026 Jan 30, 2026 Jan 29, 2026 Jan 28, 2026 Jan 27, 2026 Jan 26, 2026 Jan 23, 2026 Jan 22, 2026 Jan 21, 2026 Jan 20, 2026 Jan 17, 2026 Jan 16, 2026 Jan 15, 2026 Jan 14, 2026 Jan 9, 2026 Jan 8, 2026 Jan 7, 2026 Jan 6, 2026 Dec 19, 2025 Dec 18, 2025 Dec 17, 2025 Dec 12, 2025 Dec 11, 2025 Dec 10, 2025 Dec 9, 2025 Dec 6, 2025 Dec 5, 2025 Dec 4, 2025 Dec 3, 2025
24 companies Today

Taiwan Semiconductor Manufacturing Company Limited

2330.TW Q1 2026
Reported: 2026-04-16

TSMC delivered solid first quarter results with an 8.4% sequential revenue increase, driven by strong demand for advanced process nodes, and provided optimistic guidance for Q2 2026, maintaining robust profitability outlook.

Key takeaways
  • Q1 revenue rose to USD 35.9 billion, up 8.4% sequentially, with gross margin expanding to 66.2% amid improved capacity utilization and cost efficiencies.
  • Advanced technologies (7nm and below) accounted for 74% of wafer revenue, with 3nm contributing 25%, highlighting leadership in cutting-edge process adoption.
  • Q2 revenue guidance of USD 39.0–USD 40.2 billion reflects a 10% sequential growth, with gross margins projected at ~66.5%.
  • Capital expenditures for Q1 reached USD 11.1 billion; cash and marketable securities stood at USD 106 billion, supporting ongoing expansion and technology ramp-ups.
  • While geopolitical factors pose potential risks, TSMC’s diversified supply chain and energy resilience strategies aim to mitigate near-term disruptions.

Abbott Laboratories

ABT Q1 2026
Reported: 2026-04-16

Abbott delivered aligned first-quarter results with steady earnings and achieved a key strategic milestone with the acquisition of Exact Sciences, enhancing its diagnostics leadership and growth prospects.

Key takeaways
  • Adjusted EPS of $1.15 met guidance despite headwinds from early financing costs and a weaker respiratory season.
  • Completed the Exact Sciences acquisition, adding ~$3 billion in expected 2026 sales and accelerating long-term growth trajectory.
  • Diagnostics sales grew 2%, with Core Lab up 3%, while Molecular Diagnostics declined 10% due to weaker respiratory testing demand.
  • Cancer Diagnostics posted 13% growth driven by strong international performance and Cologuard.
  • Medical Devices revenue increased 8.5%, led by robust cardiovascular product sales, supported by pipeline advancements and clinical trial initiatives.

Barry Callebaut AG

BARN.SW Q2 2026
Reported: 2026-04-16

Barry Callebaut delivered a challenging first half, impacted by volume declines and operational disruptions, but has begun laying the groundwork for recovery through strategic refocus and cost savings.

Key takeaways
  • Volume declines and supply chain issues amid industry volatility led to lower sales and market share erosion.
  • The Next Level program delivered CHF 150 million in savings but contributed to capacity constraints and quality incidents.
  • Leadership’s initial assessment emphasizes the need to simplify operations, prioritize core fundamentals, and accelerate execution of the Focus for Growth plan.
  • Cocoa prices declined sharply, providing a potential tailwind for improving margins and supporting demand recovery.
  • The company remains confident in its market position and long-term growth potential, centered on strong customer relationships and key categories.

Community

See what investors are trading, holding, and sharing

🌐
All
📈
Stock
📊
ETF
🏦
Mutual Fund
🪙
Crypto
💱
Forex
# Asset Price Community % Type Currency Sector
Loading...